The ability of primate immunodeficiency viruses to mutate rapidly will require a successful vaccine to provide broad-based protection against antigenically diverse virus strains. Exposure to such disparate strains can occur within the host during chronic infection, because the high mutation rate generates viral quasi species, and through multiple episodes of virus exposure. Of potential concern is the possibility that vaccination will compromise the immune system's ability to respond to antigenically diverse strains later on. This concept, first entitled original antigenic sin (OAS), has been described more recently as deceptive imprinting [1, 2] .
"OAS" was first used to describe antibody responses to influenza virus. Exposure to one strain of influenza virus through vaccination or infection may induce antibody responses specific to that strain. Subsequent exposure to a somewhat divergent strain has been shown to induce an anamnestic antibody response that is specific for the initial strain of influenza [1, 3] .
Influenza virus hemagglutinin and neuraminidase molecules, the major targets of neutralizing antibody (NAb) responses, mutate rapidly [4] . The NAb responses in human immunodeficiency virus (HIV) infection are targeted to surface glycoprotein gp120 and transmembrane gp41. HIV envelope glycoproteins change rapidly, especially in the hypervariable gp120 regions. It has been suggested that the initial antibody response to immunodominant epitopes of the hypervariable V3 loop of gp120, which preferentially neutralizes T cell line-adapted HIV strains, impedes NAb responses to epitopes on HIV variants that circulate in an infected individual and rapidly mutate under immune selection pressure [5, 6] . OAS is, thus, a potential problem during chronic HIV infection, as novel viral quasi species emerge through rapid mutation or with subsequent exposure to divergent HIV strains. OAS is also a potential problem for effective NAb formation against nonhomologous HIV strains in AIDS vaccine recipients with breakthrough infections and for designing multivalent anti-HIV envelope vaccines.
Herein we describe the NAb responses of a set of vaccinated macaques that became infected after intravenous challenge with simian-human immunodeficiency virus (SHIV)-IIIB and were later experimentally superinfected with heterologous SHIV89.6P. 
Methods
Animals, vaccination, and virus challenges. Rhesus monkeys (Macaca mulatta) were housed at the Yerkes Regional Primate Research Center, Emory University. The animals were part of a larger pilot vaccine study, the details of which are described elsewhere [7] . The schedule of the vaccinations and subsequent intravenous virus challenges is shown in figure 1 . In brief, animals RFw-5 and RMw-5 were inoculated with DNA plasmids encoding gag, pol, and nef of SIVmac239 and env of HIV-IIIB. Four inoculations, starting within hours of birth, were given over 11 months, with recombinant interleukin-12 included each time as an adjuvant. Ten months later, the animals received 2 booster inoculations with recombinant, homologous gp160, at which time age-matched animal RGt-5 was enrolled. RGt-5 received only HIV-IIIB gp160 inoculations.
The animals were challenged with homologous SHIV-vpu + , a strain that encodes the HIV-IIIB envelope gene, 2 weeks after the final gp160 booster inoculation. Although sterilizing immunity was not observed, all 3 animals showed evidence of virus containment, relative to control animals. Three months later, the animals were challenged a second time with homologous SHIV-vpu + , and 2 months after that they were challenged with heterologous SHIV89.6P. All 3 animals had evidence of both SHIV89.6P and SHIV-vpu + infection after SHIV89.6P challenge, as detected by differential DNA polymerase chain reaction.
Serologic assays. NAb assays were done with SHIV-IIIB (SHIV-vpu + , homologous in Env to the IIIB T cell line-adapted strain of HIV) and with SHIV89.6P in an MT-2 cell-killing assay, as described elsewhere [8, 9] . Neutralization titer in this assay is the reciprocal plasma dilution required to protect 50% of cells from virus-induced killing. Cell-free stocks of SHIV-IIIB and SHIV89.6P were prepared in H9 cells and human peripheral blood mononuclear cells, respectively.
To measure the V3-loop specificity of NAbs before SHIV89.6P challenge, serum samples were incubated in the presence or absence of IIIB or 89.6 V3-loop peptides (50 mg/mL) and then were tested for neutralizing activity against SHIV-IIIB, as described elsewhere [8] . V3-loop peptide-specific binding antibodies were measured by ELISA [8] .
The V3 amino acid sequences are TRPNNNTRKSIRIQRGPGR-AFVTIGKIGNMRQ for strain IIIB and TRPNNNTRERLSI-GPG-RAFYARRNIIGDIRQ for strain 89.6P.
Results
Initial NAb responses. To test whether NAbs can be induced against a heterologous strain of SHIV after initial vaccination and infection with an antigenically distinct SHIV variant, we examined NAb responses in 3 macaques that were enrolled as part of a larger pilot study. These animals became dually infected. The initial goal of that study was to assess the safety and immunogenicity in neonatal macaques of a DNA prime/protein booster vaccination protocol against challenge with SHIV (figure 1; authors' unpublished data). Animals RFw-5 and RMw-5 were inoculated with DNA that included plasmids encoding env of HIV-IIIB, and they twice received booster inoculations of recombinant, homologous gp160, at which time the age-matched animal RGt-5 was enrolled. RGt-5 received only HIV-IIIB gp160 inoculations. All 3 animals were challenged twice with homologous SHIV-vpu + , a strain that encodes the HIV-IIIB envelope gene. The animals were subsequently challenged with heterologous SHIV89.6P.
Anti-HIV-IIIB Env antibodies were detected by ELISA in both RFw-5 and RMw-5 after the fourth DNA inoculation [7] . However, DNA vaccination alone induced no detectable NAbs in either animal. NAbs against SHIV-IIIB, a chimeric virus containing an env gene homologous to those of HIV-IIIB and SHIVvpu + , were first detected after a single gp160 boost in animal RMw-5 (titer of 32) and after a second gp160 boost in animal RFw-5 (titer of 2010). Animal RGt-5 received only gp160 inoculations, and SHIV-IIIB-directed NAb responses were detected after the second gp160 inoculation (titer of 410). Serum samples from all 3 animals could neutralize SHIV-vpu + at the time of SHIV89.6P challenge. Of importance, before SHIV89.6P challenge, no SHIV89.6P-reactive NAbs were detected in any animal ( figure 2) .
The V3-loop specificities of SHIV-IIIB-directed NAb responses from the 3 SHIV-vpu + -challenged animals were also evaluated, by measuring the reduction in neutralization titers against SHIV-IIIB after adding homologous V3-loop peptide to plasma samples. As shown in figure 3A , addition of HIV-IIIB V3-loop peptides reduced the neutralization titers of animals RFw-5 and RGt-5 by 94% and 75%, respectively, and that of animal RMw-5 by . 50%; in the latter animal, neutralization was reduced below the level of detection. As a relevant negative control, the addition of strain 89.6 V3-loop peptide had no effect on NAb titers against SHIV-IIIB in serum from any animal. This demonstrates that, before challenge with SHIV89.6P, a large measure of the NAb activity against SHIV-IIIB in the 3 animals was directed to neutralization epitopes on the V3 loop. In agreement with these results, serum samples from animals RFw-5 and, to a lesser extent, RMw-5 and RGt-5, contained antibodies reactive with a IIIB-V3 loop peptide, as determined by ELISA ( figure 3B ). These same serum samples had no detectable antibodies to V3-loop peptides of strains 89.6 and 89.6P ( figure 3B) .
Emergence of potent anti-SHIV89.6P NAb responses. After challenge with pathogenic SHIV89.6P, all 3 animals developed potent NAb responses against this virus that were detectable by 8 weeks after challenge (titers of 240-310; figure 2 ). The titers fluctuated thereafter and were . 1000 at multiple time points for each animal. Also, although the SHIV89.6P challenge induced reactivation of SHIV-vpu + viremia [7] , no anamnestic NAb responses against the first virus were seen in 2 of the 3 monkeys. The third animal, RGt-5, had minor increases in NAbs against SHIV-vpu + that could reflect normal assay variation or a mild response to the recurrent SHIV-vpu + viremia. Nonetheless, this response to the original SHIV-vpu + did not prevent a potent NAb response from developing against the heterologous SHIV89.6P challenge virus. It is noteworthy that no NAbs to SHIV89.6P were detected in any monkey on several occasions before challenge with this virus. This pattern of NAb seroconversion is similar to that of SHIV89.6P infection in SHIV89.6P-naive animals that recovered from the rapid immunosuppressive effects of the virus [10] .
Discussion
In the 3 monkeys studied, the possibility existed that stimulation of memory B cells specific for antigenic determinants on HIV-IIIB envelope glycoproteins by cross-reactive SHIV89.6P antigens would preempt a humoral response to strain-specific SHIV89.6P determinants. This possibility was based on the concept of OAS, according to which stimulation of memory B cells by new but related antigens can result in augmented production of antibodies specific for the original antigen [1] . The production of antibodies against the new antigen is actively suppressed or down-regulated by the memory B cells and the presence of small amounts of antibodies to the original antigen. The concept of deceptive imprinting expands this idea, suggesting that immunodominant epitopes on the original antigen induce a clonally restricted B cell response repertoire [6, 11] . Neutralization of novel antigenic strain variants that the host may subsequently encounter, either through mutation or by secondary exposure, may then be compromised because of this clonal restriction. Thus, the induction of NAbs against SHIV89.6P in our 3 monkeys indicates that the combination of DNA prime/protein booster inoculation plus SHIV-vpu + breakthrough infection did not subject the animals to OAS or deceptive imprinting, which would have prevented them from mounting subsequent antibody responses to neutralizing epitopes of SHIV89.6P.
Any clinically applicable AIDS vaccine needs to be efficacious against a broad range of heterologous viruses that individuals may be exposed to over a lifetime. Locher et al. [5] suggested OAS as a possible negative consequence of vaccination against HIV. In volunteers who were vaccinated with HIVSF2-derived gp120 and later became infected, the infection boosted SF2 gp120-specific NAb levels within 3 months [5] . It should be noted, however, that NAbs specific for the breakthrough infecting viruses developed subsequently in all 3 vaccinated subjects [5] .
In another study using a SHIV/macaque model, it was suggested that OAS might have prevented the broadening of protective immunity. Animals vaccinated with HIVSF2 Env and challenged with closely related SHIV(SF13) were protected from infection. However, heterologous boosting with either V2 and V3 peptides or gp120 of SF33 failed to protect against SHIV(SF33) challenge [12] . Since NAbs were never measured, it is not possible to make a comparison with our results.
An additional important point of our study concerns the epitope specificity of the initial NAb response to immunodeficiency virus infection or vaccination as it relates to OAS or deceptive imprinting. It has been postulated that the V3 loop contains immunodominant decoy epitopes and that deceptive imprinting occurs through initial NAb responses to these epitopes [2, 13] . In our animals, peptide inhibition analysis showed that the bulk of the SHIV-IIIB NAb activity detected before challenge with SHIV89.6P was V3 loop directed. Thus, despite this early V3 loop reactivity, deceptive imprinting did not occur and prevent the induction of NAbs to the 89.6P strain of SHIV.
Because the original purpose of this work was to assess the safety and immunogenicity of DNA prime/protein booster vaccine in neonatal macaques, this study only examined NAb responses against SHIV-IIIB and SHIV89.6P. The V3 loops of strains IIIB and 89.6P are , 60% homologous in their amino acid sequence and thus are quite divergent. Furthermore, V3-specific antibodies induced by SHIV-IIIB infection, which can neutralize SHIV-IIIB, cannot neutralize SHIV89.6P, and vice versa [8] , indicating that the V3 loops of these 2 viruses also are heterologous serologically. These properties of strains IIIB and 89.6P make them ideal candidates for testing the concept of OAS in the lentivirus family. Since no evidence of OAS was found in this study, work is now under way to expand this finding and examine NAb responses in macaques immunized against or infected with other SHIV variants, including more closely related ones.
